Related references
Note: Only part of the references are listed.Breast Cancer Recurrence Diagnosis Suspected on Tumor Marker Rising Value of Whole-Body 18FDG-PET/CT Imaging and Impact on Patient Management
Laurence Champion et al.
CANCER (2011)
Heterogeneity of Metabolic Response to Systemic Therapy in Metastatic Breast Cancer Patients
V. Huyge et al.
CLINICAL ONCOLOGY (2010)
17β-Estradiol Augments 18F-FDG Uptake and Glycolysis of T47D Breast Cancer Cells via Membrane-Initiated Rapid PI3K-Akt Activation
Bong-Ho Ko et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET
Michal E. Schneider-Kolsky et al.
BREAST CANCER RESEARCH (2010)
Third consensus on medical treatment of metastatic breast cancer
S. Beslija et al.
ANNALS OF ONCOLOGY (2009)
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer
Farrokh Dehdashti et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer
Joan Duch et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F] Fluorodeoxyglucose
Joerg Schwarz-Dose et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer
Paula Lindholm et al.
NUCLEAR MEDICINE COMMUNICATIONS (2009)
Bone metastases in patients with metastatic breast cancer: Morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT
Ukihide Tateishi et al.
RADIOLOGY (2008)
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy
Alina Berriolo-Riedinger et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M. Kaufmann et al.
ANNALS OF ONCOLOGY (2007)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Imaging early changes in proliferation at 1 week post chemotherapy:: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography
Laura Kenny et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
Jennifer M. Specht et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Fusion of metabolic function and morphology:: Sequential [18F] fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer
Yong Du et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Monitoring primary breast cancer throughout chemotherapy using FDG-PET
Garry M. McDermott et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography
Caroline Rousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sequential positron emission tomography using [18F] fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer
Olivier Couturier et al.
CLINICAL CANCER RESEARCH (2006)
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
Hannah M. Linden et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
M Dowsett et al.
CLINICAL CANCER RESEARCH (2006)
Usefulness of 3 '-[F-18]fluoro-3 '-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy
BS Pio et al.
MOLECULAR IMAGING AND BIOLOGY (2006)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bone imaging in metastatic breast cancer
T Hamaoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
FDG uptake in breast cancer:: correlation with biological and clinical prognostic parameters
A Buck et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2002)
Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography
R Bos et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial
MJ Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer
JE Mortimer et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
IC Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
M Schelling et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
